BR0307496A - Uso de uma neurotoxina clostridiana, bem como composição farmacêutica utilizável no tratamento de um distúrbio da glândula mamária - Google Patents

Uso de uma neurotoxina clostridiana, bem como composição farmacêutica utilizável no tratamento de um distúrbio da glândula mamária

Info

Publication number
BR0307496A
BR0307496A BR0307496-0A BR0307496A BR0307496A BR 0307496 A BR0307496 A BR 0307496A BR 0307496 A BR0307496 A BR 0307496A BR 0307496 A BR0307496 A BR 0307496A
Authority
BR
Brazil
Prior art keywords
treatment
well
pharmaceutical composition
mammary gland
clostridial neurotoxin
Prior art date
Application number
BR0307496-0A
Other languages
English (en)
Inventor
Mitchell F Brin
Stephen Donovan
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32867445&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0307496(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BR0307496A publication Critical patent/BR0307496A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Processing Of Meat And Fish (AREA)

Abstract

"USO DE UMA NEUROTOXINA CLOSTRIDIANA, BEM COMO COMPOSIçãO FARMACêUTICA UTILIZáVEL NO TRATAMENTO DE UM DISTúRBIO DA GLâNDULA MAMáRIA". A presente invenção refere-se a um método para o tratamento de distúrbio de glândula mamária, incluindo tecido hiperplásico, hipertónico, cístico e/ou neoplásico de glândula mamária, por administração local de uma toxina botulínica em ou na proximidade do tecido de mama afetado.
BR0307496-0A 2002-02-08 2003-02-04 Uso de uma neurotoxina clostridiana, bem como composição farmacêutica utilizável no tratamento de um distúrbio da glândula mamária BR0307496A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/071,826 US7838007B2 (en) 1999-12-07 2002-02-08 Methods for treating mammary gland disorders
PCT/US2003/003479 WO2004071525A1 (en) 2002-02-08 2003-02-04 Methods for treating mammary gland disorders

Publications (1)

Publication Number Publication Date
BR0307496A true BR0307496A (pt) 2005-06-28

Family

ID=32867445

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307496-0A BR0307496A (pt) 2002-02-08 2003-02-04 Uso de uma neurotoxina clostridiana, bem como composição farmacêutica utilizável no tratamento de um distúrbio da glândula mamária

Country Status (12)

Country Link
US (2) US7838007B2 (pt)
EP (3) EP1728517A3 (pt)
JP (2) JP4889220B2 (pt)
AT (1) ATE331527T1 (pt)
AU (1) AU2003225549B2 (pt)
BR (1) BR0307496A (pt)
CA (1) CA2478902C (pt)
DE (1) DE60306505T2 (pt)
DK (1) DK1492561T3 (pt)
ES (1) ES2264041T3 (pt)
PT (1) PT1492561E (pt)
WO (1) WO2004071525A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838008B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US7838007B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating mammary gland disorders
AU2001270219A1 (en) * 2000-06-28 2002-01-08 Ira Sanders Methods for using tetanus toxin for benificial purposes in animals (mammals)
US7824693B2 (en) 2002-08-19 2010-11-02 Ira Sanders Treatment of fine wrinkles with clostridia neurotoxins
US7288259B2 (en) * 2002-08-19 2007-10-30 Ira Sanders Treatment of holocrine gland dysfunction with clostridia neurotoxins
US20120114697A1 (en) 2002-08-19 2012-05-10 Ira Sanders Treatment of holocrine gland dysfunction with clostridia neurotoxins
WO2004066928A2 (en) * 2003-01-24 2004-08-12 Albert Einstein College Of Medicine Of Yeshiva University Use of mycobacterial vaccines in cd4+ or cd8+ lymphocyte-deficient mammals
EP2633856A3 (en) * 2003-05-09 2014-01-01 The Trustees of The University of Pennsylvania ATP citrate lyase inhibitors for treating cancer
US8048423B2 (en) * 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders
US8871224B2 (en) * 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
EP1778078A2 (en) * 2004-07-20 2007-05-02 Allergan, Inc. Thermographic assessment of clostridial toxin applications
US20070258900A1 (en) * 2004-07-20 2007-11-08 Joseph Francis Blood Flow Assessment of Clostridial Toxin Applications
US8343929B2 (en) * 2004-09-23 2013-01-01 Toxcure, Inc. Treating neoplasms with neurotoxin
WO2006034404A2 (en) * 2004-09-23 2006-03-30 Toxcure, Inc. Treating neoplasms with neurotoxin
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
US8155408B2 (en) * 2008-04-15 2012-04-10 General Electric Company Standardized normal database having anatomical phase information
ES2599033T3 (es) 2008-11-26 2017-01-31 Toxcure, Inc. Tratamiento de neoplasias con neurotoxina
US8629103B2 (en) 2010-12-02 2014-01-14 New York University Treatment of non-proliferative cystic disease of the breast
WO2012097189A1 (en) * 2011-01-13 2012-07-19 Rutgers, The State University Of New Jersey Systems and methods for multi-protocol registration and tissue classification using local morphologic scale (lms)
BR112014000634A2 (pt) 2011-07-14 2017-02-14 Allergan Inc métodos para tratamento de incontinência associada com atividade sexual
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
AU2013246882B2 (en) 2012-04-13 2017-10-19 Lubrizol Advanced Materials, Inc. Compounds which inhibit neuronal exocytosis (II)
EP3843777A4 (en) 2018-08-28 2022-05-04 Ira Sanders THERAPEUTICS FOR THE SKIN

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4664911A (en) 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
US5183462A (en) * 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US5466672A (en) 1992-12-04 1995-11-14 Ophidian Pharmaceuticals, Inc. Therapeutic use of clostridium difficile toxin A
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US5670484A (en) * 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
ATE292977T1 (de) 1994-05-09 2005-04-15 William J Binder Präsynaptische neurotoxine gegen migränekopfschmerzen
US5595740A (en) 1994-05-16 1997-01-21 University Of Florida Cloning of non-IgA FC binding forms of the group B streptococcal beta antigens
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US6143037A (en) * 1996-06-12 2000-11-07 The Regents Of The University Of Michigan Compositions and methods for coating medical devices
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
ES2385130T3 (es) * 1997-07-15 2012-07-18 The Regents Of The University Of Colorado, A Body Corporate Uso de terapia con neurotoxinas para el tratamiento de enfermedades urológicas y de enfermedades relacionadas
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
DE19802569A1 (de) 1998-01-23 1999-09-09 Univ Albert Ludwigs Freiburg Toxikologisch aktive Fragmente des lethalen Toxins von Clostridium sordellii und deren Verwendung in Immuntoxinen
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
MXPA01004254A (es) 1998-10-27 2002-04-24 Mayo Foundation Metodos para intensificar la curacion de heridas.
DE19852981A1 (de) 1998-11-17 2000-05-18 Martin Schmidt Botulinum-Toxine, deren Derivate, Analoge und molekulare Bruchstücke zur topischen epicutanen Anwendung auch in Zusammenwirken mit hautpenetrationsfördernden Substanzen und Maßnahmen in Zubereitungsformen zur Beeinflussung acetylcholinabhängiger Körperfunktionen
DE19856052A1 (de) 1998-12-04 2000-06-08 Deutsches Krebsforsch Konjugat zur Anreicherung in neuronalen Zellen
GB9907429D0 (en) 1999-03-31 1999-05-26 Microbiological Res Authority Modulation of C-fibre activity
EP1135094B1 (en) 1999-04-16 2009-03-11 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
GB9922554D0 (en) 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6265379B1 (en) 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US7838007B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating mammary gland disorders
US6139845A (en) * 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6261572B1 (en) 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US6143306A (en) 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6641820B1 (en) 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
AU2001276005A1 (en) 2000-08-02 2002-02-13 Allergan Sales, Inc. Method for treating a neoplasm
US6831059B2 (en) 2000-10-20 2004-12-14 Allergan, Inc. Compositions and methods for treating gonadotrophin related illnesses

Also Published As

Publication number Publication date
JP4889220B2 (ja) 2012-03-07
DE60306505D1 (de) 2006-08-10
ATE331527T1 (de) 2006-07-15
EP2204183A1 (en) 2010-07-07
EP1728517A2 (en) 2006-12-06
JP2006510723A (ja) 2006-03-30
US20020094339A1 (en) 2002-07-18
WO2004071525A1 (en) 2004-08-26
AU2003225549B2 (en) 2006-11-16
AU2003225549A1 (en) 2004-09-06
EP1728517A3 (en) 2008-06-25
US7838007B2 (en) 2010-11-23
ES2264041T3 (es) 2006-12-16
EP1492561A1 (en) 2005-01-05
US20050260231A1 (en) 2005-11-24
PT1492561E (pt) 2006-10-31
US7846456B2 (en) 2010-12-07
EP1492561B1 (en) 2006-06-28
JP2012025775A (ja) 2012-02-09
CA2478902A1 (en) 2004-08-26
DK1492561T3 (da) 2006-09-25
CA2478902C (en) 2012-05-01
DE60306505T2 (de) 2007-01-11

Similar Documents

Publication Publication Date Title
BR0307496A (pt) Uso de uma neurotoxina clostridiana, bem como composição farmacêutica utilizável no tratamento de um distúrbio da glândula mamária
BRPI0612119A2 (pt) tratamento de distúrbio auto-imunes com uma neuroxotina
ES2526912T3 (es) Composición farmacéutica que contiene neurotoxina botulínica A2
BR0309888A (pt) Tratamento intracraniano de distúrbios neuropsiquiátricos por neurotoxinas clostridiais tal como a toxina da botulina
DK1521593T3 (da) Transdermale botulinumtoksinforbindelser
BRPI0411316A (pt) uso de uma toxina clostrìdica para reduzir o apetite
BR0111698A (pt) Método para o tratamento de um distúrbio de movimento
BR0316027A (pt) Formulações de toxina botulina para administração oral
BRPI0417493A (pt) terapia com toxina botulìnica para distúrbios da pele
BRPI0516836A (pt) composições de neurotoxina cosméticas compreendendo um componente de toxina botulina e métodos
BR0310099A (pt) método para tratar dislipidemia ou uma doença associada com a dislipidemia
PT1349856E (pt) Compostos de isoindolina-1-ona activadores da glicocinase
BRPI0910993A2 (pt) técnica de administração na linha de sutura usando toxinas botulínicas
DK1322324T3 (da) Fremgangsmåder til behandling af muskelskader
ATE451916T1 (de) Ophthalmische pharmazeutische zusammensetzungen auf basis von aminosäuren und natriumhyaluronat
DE50306232D1 (de) Ampholytisches copolymer und dessen verwendung
ATE380542T1 (de) Topische zusammensetzung enthaltend mindestens ein vitamin d oder vitamin d analogon und mindestens ein corticosteroid
ECSP10010042A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
BRPI0519243A2 (pt) mÉtodos e composiÇÕes para tratar doenÇas relacionadas a amilàide
RS54372B1 (en) COLLAGENASIS FOR TREATMENT OF CELLULITE
AR064706A1 (es) Composiciones y metodos para aplicacion topica y suministro transdermico de toxinas de botulina estabilizadas con fragmentos de polipeptido derivados de hiv -tat
BR0312099A (pt) Uso de toxina bolutìnica, bem como composição farmacêutica
ATE472529T1 (de) Prolinamidderivate als natriumkanalmodulatoren
ECSP088430A (es) Diarilurea para el tratamiento de hipertensión pulmonar
DK1784205T3 (da) Strækmærkebehandling med botulinumtoksin

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2308 DE 31/03/2015.